Molecular Neuroimaging in Alzheimer's Disease

NeuroRx

Volumn 1, Issue 2, 2004, Pages 206-212

  Jagust, William ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's; blood flow; functional imaging; glucose metabolism; molecular imaging; PET; SPECT

Indexed keywords

AGING; ALZHEIMER DISEASE; ARTICLE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HUMAN; MOLECULAR BIOLOGY; NEUROIMAGING; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; REVIEW; SCINTISCANNING;

ALZHEIMER DISEASE; BRAIN; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 23844554898     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.1.2.206     Document Type: Article

References (60)

1. Kety S. Human cerebral blood flow and oxygen consumption as related to aging. Res Publ Assoc Res Nerv Ment Dis 35 (1956) 31-45
2. Frackowiak R., Pozzili C., Legg N., Du Boulay G., Marshall J., Lenzi L., et al. Regional cerebral oxygen supply and utilization in dementia: a clinical and physiological study with oxygen-15 and positron tomography. Brain 104 (1981) 753-778
3. Friedland R., Budinger T., Ganz E., Yano Y., Mathis C., Koss B., et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]Fluorodeoxyglucose. J Comput Assist Tomogr 7 (1983) 590-598
4. Benson D., Kuhl D., Hawkins R., Phelps M., Cummings J., and Tsai S. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 40 (1983) 711-714
5. Johnson K., Mueller S., Walshe T., English R., and Holman B. Cerebral perfusion imaging in Alzheimer's disease: use of single photon emission computed tomography and iofetamine hydrochloride I 123. Arch Neurol 44 (1987) 165-168
6. Jagust W., Budinger T., and Reed B. The diagnosis of dementia with single photon emission computed tomography. Arch Neurol 44 (1987) 258-262
7. Minoshima S., Giordani B., Berent S., Frey K., Foster N., and Kuhl D. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42 (1997) 85-94
8. Johnson K., Holman B., Rosen T., Nagel J., English R., and Growdon J. Iofetamine I 123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer's disease. Arch Intern Med 150 (1990) 752-756
9. Eberling J., Jagust W., Reed B., and Baker M. Reduced temporal lobe blood flow in Alzheimer's disease. Neurobiol Aging 13 (1992) 483-491
10. Minoshima S., Frey K., Koeppe R., Foster N., and Kuhl D. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36 (1995) 1238-1248
11. Johnson K., Jones K., Holman B., Becker J., Spiers P., Satlin A., et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50 (1998) 1563-1571
12. Herholz K. PET studies in dementia. Ann Nucl Med 17 (2003) 79-89
13. Miller B., Cummings J., Villaneuva-Meyer J., Boone K., Mehringer C., Lesser I., et al. Frontal lobe degeneration: clinical, neuropsychological, and SPECT characteristics. Neurology 41 (1991) 1374-1382
14. Ishii K., Sakamoto S., Sasaki M., Kitagaki H., Yamaji S., Hashimoto M., et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 39 (1998) 1875-1878
15. Santens P., De Bleecker J., Goethals P., Strijckmans K., Lemahieu I., Slegers G., et al. Differential regional cerebral uptake of (18)F-fluoro-2-deoxy-d-glucose in Alzheimer's disease and frontotemporal dementia at initial diagnosis. Eur Neurol 45 (2001) 19-27
16. Albin R., Minoshima S., D'Amato C., Frey K., Kuhl D., and Sima A. Fluorodeoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 47 (1996) 462-466
17. Imamura T., Ishii K., Sasaki M., Kitagaki H., Yamaji S., Hirono N., et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci Lett 235 (1997) 49-52
18. Lobotesis K., Fenwick J., Phipps A., Ryman A., Swann A., Ballard C., et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56 (2001) 643-649
19. Duara R., Barker W., Loewenstein D., Pascal S., and Bowen B. Sensitivity and specificity of positron emission tomography and magnetic resonance imaging studies in Alzheimer's disease and multi-infarct dementia. Eur Neurol 29 Suppl 3 (1989) 9-15
20. Kwan L., Reed B., Eberling J., Schuff N., Tanabe J., Norman D., et al. Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function. Arch Neurol 56 (1999) 809-814
21. Sultzer D., Mahler M., Cummings J., Van Gorp W., Hinkin C., and Brown C. Cortical abnormalities associated with subcortical lesions in vascular dementia. Arch Neurol 52 (1995) 773-780
22. Foster N., Chase T., Mansi L., Brooks R., Fedio P., Patronas N., et al. Cortical abnormalities in Alzheimer's disease. Ann Neurol 16 (1984) 649-654
23. Waldemar G., Walovitch R., Andersen A., Hasselbalch S., Bigelow R., Joseph J., et al. 99mTc-bicisate (neurolite) SPECT brain imaging and cognitive impairment in dementia of the Alzheimer type: a blinded read of image sets from a multicenter SPECT trial. J Cereb Blood Flow Metab 14 Suppl 1 (1994) S99-S105
24. Kawano M., Ichimiya A., Ogomori K., Kuwabara Y., Sasaki M., Yoshida T., et al. Relationship between both IQ and Mini-Mental State Examination and the regional cerebral glucose metabolism in clinically diagnosed Alzheimer's disease: a PET study. Dement Geriatr Cogn Disord 12 (2001) 171-176
25. Alexander G., Chen K., Pietrini P., Rapoport S., and Reiman E. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159 (2002) 738-745
26. Jobst K., Barnetson L., and Shepstone B. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and ApoE4 in medial temporal lobe dementias. Int Psychogeriatr 10 (1998) 271-302
27. Bonte F., Weiner M., Bigio E., and White C. Brian blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 202 (1997) 793-797
28. Read S., Miller B., Mena I., Kim R., Itabashi H., and Darby A. SPECT in dementia: clinical and pathological correlation. J Am Geriatr Soc 43 (1995) 1243-1247
29. Hoffman J., Welsh-Bohmer K., Hanson M., Crain B., Hulette C., Earl N., et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41 (2000) 1920-1928
30. Silverman D., Small G., Chang C., Lu C., Kung De Aburto M., Chen W., et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286 (2001) 2120-2127
31. Knopman D., DeKosky S., Cummings J., Chui H., Corey-Bloom J., Relkin N., et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (2001) 1143-1153
32. Jagust W., Thisted R., Devous Sr. M., Van Heertum R., Mayberg H., Jobst K., et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 56 (2001) 950-956
33. Consensus report of the Working Group on: Molecular and biochemical markers of Alzheimer's disease. Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 19 (1998) 109-116
34. Haan M., Mungas D., Gonzalez H., Ortiz T., Acharya A., and Jagust W. Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc 51 (2003) 169-177
35. Helmer C., Joly P., Letenneur L., Commenges D., and Dartigues J. Mortal with dementia: results from a French prospective community-based cohort. Am J Epidemiol 154 (2001) 642-648
36. Mielke R., Herholz K., Grond M., Kessler J., and Heiss W.-D. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging 13 (1991) 93-98
37. Grady C., Haxby J., Horwitz B., Berg G., and Rapoport S. Neuropsychological and cerebral metabolic function in early vs late onset dementia of the Alzheimer type. Neuropsychologia 25 (1987) 807-816
38. Small G., Kuhl D., Riege W., Fujikawa D., Ashford J., Metter J., et al. Cerebral glucose metabolic patterns in Alzheimer's disease: effect of gender and age at dementia onset. Arch Gen Psychiatry 46 (1989) 527-532
39. Kemp P., Holmes C., Hoffmann S., Bolt L., Holmes R., Rowden J., et al. Alzheimer's disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia. J Neurol Neurosurg Psychiatry 74 (2003) 715-719
40. DeCarli C., Grady C., Clark C., Katz D., Brady D., Murphy D., et al. Comparison of positron emission tomography, cognition and brain volume in Alzheimer's disease with and without severe abnormalities of white matter. J Neurol Neurosurg Psychiatry 60 (1996) 158-167
41. Stern Y., Alexander G., Prohovnik I., and Mayeux R. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease. Ann Neurol 32 (1992) 371-375
42. Jagust W., Eberling J., Wu C., Finkbeiner A., Mungas D., Valk P., et al. Brain function and cognition in a community sample of elderly Latinos. Neurology 59 (2002) 378-383
43. Scheltens P., Launer L., Barkhof F., Weinstein H., and Jonker C. The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single photon emission computed tomography for the diagnosis of Alzheimer's disease in a community dwelling elderly population. Alzheimer Dis Assoc Disord 11 (1997) 63-70
44. Wolfe N., Reed B., Eberling J., and Jagust W. Temporal lobe perfusion on single photon emission computed tomography predicts the rate of cognitive decline in Alzheimer's disease. Arch Neurol 52 (1995) 257-262
45. Jagust W., Haan M., Eberling J., Wolfe N., and Reed B. Functional imaging predicts cognitive decline in Alzheimer's disease. J Neuroimaging 6 (1996) 156-160
46. Jagust W., Haan M., Reed B., and Eberling J. Brain perfusion imaging predicts survival in Alzheimer's disease. Neurology 51 (1998) 1009-1013
47. Reiman E., Caselli R., Yun L., Chen K., Bandy D., Minoshima S., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med 334 (1996) 752-758
48. Kennedy A., Frackowiak R., Newman S., Bloomfield P., Seaward J., Roques P., et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 186 (1995) 17-20
49. Petersen R., Smith G., Waring S., Ivnik R., Tangalos E., and Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56 (1999) 303-308
50. De Santi S., deLeon M., Rusinek H., Convit A., Tarshish C., Roche A., et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22 (2001) 529-539
51. de Leon M., Convit A., Wolf O., Tarshish C., DeSanti S., Rusinek H., et al. Prediction of cognitive decline in normal elderly subjects with 2- [(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 98 (2001) 10966-10971
52. Small G., Ercoli L., Silverman D., Huang S., Komo S., Bookheimer S., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 97 (2000) 6037-6042
53. Arnaiz E., Jelic V., Almkvist O., Wahlund L., Winblad B., Valind S., et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. NeuroReport 12 (2001) 851-855
54. Chetelat G., Desgranges B., De La Sayette V., Viader F., Eustache F., and Baron J. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 60 (2003) 1374-1377
55. Tune L., Tiseo P., Ieni J., Perdomo C., Pratt R., Votaw J., et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 11 (2003) 169-177
56. Mega M., Cummings J., O'Connor S., Dinov I., Reback E., Felix J., et al. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 14 (2001) 63-68
57. Nobili F., Koulibaly M., Vitali P., Migneco O., Mariani G., Ebmeier K., et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med 43 (2002) 983-990
58. Nakano S., Asada T., Matsuda H., Uno M., and Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 42 (2001) 1441-1445
59. Reiman E., Caselli R., Chen K., Alexander G., Bandy D., and Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 98 (2001) 3334-3339
60. Schneider L., Olin J., Lyness S., and Chui H. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc 45 (1997) 923-928